Skip to main content

Table 1 Patient characteristics and association with baseline mTBI (N = 20)

From: Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

Characteristic N (%) Baseline mTBI (%)
Median (IQR)
P Value
All patients 20   
Age (years), median 60 (34–76)   
Age group
 < 60 11 (55.0) 3.62 (0.90–27.54)
 60+ 9 (45.0) 23.79 (4.11–48.52) 0.2601
Gender
 Female 6 (30.0) 3.24 (0.00–4.11)
 Male 14 (70.0) 38.72 (6.80–57.99) 0.0111
ECOG
 0 15 (75.0) 5.00 (1.24–38.72)
 1 5 (25.0) 45.52 (6.37–73.77) 0.0978
Primary tumor site
 Left-side colon 16 (80.0) 9.01 (1.38–44.57)
 Right-side colon 4 (20.0) 13.71 (3.34–60.85) 0.8198
Synchronicity of metastasis
 Metachrone 10 (50.0) 12.49 (1.65–45.9)
 Synchrone 10 (50.0) 7.20 (2.43–46.3) 1.0000
Primary tumor(s)
 Resected 15 (75.0) 5.00 (1.79–38.72)
 Unresected 5 (25.0) 41.70 (4.70–59.36) 0.3941
Metastatic site(s)
 1 without peritoneum 9 (45.0) 9.40 (2.24–47.02)
 2+ without peritoneum 11 (55.0) 8.62 (1.79–38.72) 0.8817
 Peritoneum 0  
Baseline serum CEA
 Normal 5 (25.0) 1.79 (0.62–13.52)
 Elevated 15 (75.0) 16.36 (4.11–48.52) 0.0522
Chemotherapy regimen
 FOLFOX 15 (75.0) 8.62 (3.24–45.52)
 FOLFIRI 5 (25.0) 16.36 (1.52–51.94) 0.9327
Bevacizumab received
 Yes 1 (5.0) 23.79
 No 19 (95.0) 8.62 (1.79–45.52)
  1. P value indicates a significance level of < 0.05
  2. IQR interquartile range, ECOG Eastern Cooperative Oncology Group performance status, CEA carcinoembryonic antigen